Healthy Volunteers

491
Pipeline Programs
30
Companies
50
Clinical Trials
6 recruiting
3
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
473
2
5
1
1
9
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2744%
Monoclonal Antibody
1728%
Peptide
1220%
Vaccine
35%
RNA Therapeutic
23%
+ 443 programs with unclassified modality

On Market (3)

Approved therapies currently available

Novo Nordisk
OZEMPICApproved
semaglutide
Novo Nordisk
GLP-1 Receptor Agonist [EPC]subcutaneous2017
Novo Nordisk
RYBELSUSApproved
semaglutide
Novo Nordisk
oral2020
Novo Nordisk
WEGOVYApproved
semaglutide
Novo Nordisk
GLP-1 Receptor Agonist [EPC]oral2025

Competitive Landscape

130 companies ranked by most advanced pipeline stage

Novo Nordisk
32 programs
30
1
1
SemaglutidePhase 4Peptide1 trial
NNC0365-3769Phase 21 trial
Decitabine-THUPhase 11 trial
EtavopivatPhase 11 trial
EtavopivatPhase 11 trial
+27 more programs
Active Trials
NCT06291285Completed44Est. Jun 2024
NCT06581627Completed24Est. Oct 2024
NCT07023029Completed33Est. Sep 2025
+29 more trials
Pfizer
30 programs
28
2
NelfinavirPhase 4Small Molecule3 trials
artesunate sachetsPhase 41 trial
1 x 30 mg/mL pegvisomantPhase 11 trial
3 mg PF-03882845Phase 11 trial
ApixabanPhase 11 trial
+25 more programs
Active Trials
NCT01893866Completed17Est. Oct 2013
NCT01314898Completed12Est. Jun 2011
NCT02034565Completed48Est. Mar 2010
+38 more trials
GS
Gilead SciencesFOSTER CITY, CA
2 programs
1
1
Genvoya Oral dosePhase 41 trial
GS-4774Phase 11 trial
Active Trials
NCT01779505Completed60Est. Aug 2013
NCT03717129Completed12Est. Nov 2021
Moderna
2 programs
1
1
mRNA-1273.712Phase 4RNA Therapeutic1 trial
mRNA-6231Phase 1RNA Therapeutic1 trial
Active Trials
NCT04916431Completed18Est. Aug 2022
NCT06634797Completed1,000Est. Jan 2025
Jasper Therapeutics
1
Nelfinavir and OmeprazolePhase 4Small Molecule
Takeda
TakedaTOKYO, Japan
43 programs
38
3
1
TAK-816Phase 31 trial
Hepatitis A VaccinePhase 2Vaccine1 trial
NoV VaccinePhase 2Vaccine1 trial
TDVPhase 21 trial
AmphetaminePhase 11 trial
+38 more programs
Active Trials
NCT04445129Completed45Est. May 2021
NCT02959892Completed12Est. Aug 2017
NCT06268301Completed20Est. Feb 2023
+50 more trials
Sintetica
SinteticaSwitzerland - Mendriosi
1 program
1
Ocular gelPhase 2/31 trial
Active Trials
NCT04753710Completed96Est. Dec 2020
Bausch Health
4 programs
2
1
IV MethylnaltrexonePhase 21 trial
MethylnaltrexonePhase 11 trial
Rifaximin Novel FormulationPhase 11 trial
Poly-L-Lactic Acid InjectionN/A1 trial
Active Trials
NCT00869687CompletedEst. May 2010
NCT01363323CompletedEst. Feb 2005
NCT04529811CompletedEst. May 2021
+1 more trials
Ionis Pharmaceuticals
3
1
ION-682884Phase 1/21 trial
ION547Phase 11 trial
ION904Phase 11 trial
Ionis AGT-LRxPhase 11 trial
Active Trials
NCT04934891Completed48Est. Sep 2022
NCT04731623Completed40Est. Sep 2021
NCT03101878Completed62Est. Aug 2018
+1 more trials
Guerbet
2 programs
1
1
P03277Phase 1/21 trial
P03277 0.1 mmol/kgPhase 11 trial
Active Trials
NCT03657264Completed48Est. Jun 2018
NCT03603106Completed142Est. Apr 2015
E
26 programs
25
AducanumabPhase 1Monoclonal Antibody1 trial
Avatrombopag maleate 40 mgPhase 11 trial
DotinuradPhase 11 trial
E2006 2.5 mgPhase 11 trial
E2025Phase 11 trial
+21 more programs
Active Trials
NCT01306318Completed24Est. Feb 2011
NCT04924140Completed30Est. Oct 2021
NCT01759394Completed36Est. Mar 2013
+23 more trials
UP
23 programs
23
BimekizumabPhase 1Monoclonal Antibody1 trial
BimekizumabPhase 1Monoclonal Antibody1 trial
BimekizumabPhase 1Monoclonal Antibody1 trial
BrivaracetamPhase 11 trial
Brivaracetam 10 mg oral tabletPhase 11 trial
+18 more programs
Active Trials
NCT03707717Completed189Est. Jun 2019
NCT05028127Completed12Est. Jun 2016
NCT03895385Completed56Est. Oct 2019
+20 more trials
AstraZeneca
18 programs
17
AZD2373 subcutaneous injectionPhase 12 trials
AZD3293Phase 11 trial
AZD3293 oral solutionPhase 11 trial
AZD4635 50 mg nano-suspensionPhase 11 trial
AZD6244 Dosing Period 1Phase 11 trial
+13 more programs
Active Trials
NCT05351047Completed24Est. Jul 2023
NCT04269031Completed30Est. Aug 2021
NCT02126514Completed12Est. May 2014
+19 more trials
Biogen
17 programs
17
AducanumabPhase 1Monoclonal Antibody
AvonexPhase 11 trial
BIIB023 - low dose IV DosePhase 11 trial
BIIB091Phase 11 trial
BIIB095Phase 11 trial
+12 more programs
Active Trials
NCT01119677Completed120Est. Oct 2010
NCT01407406Completed48Est. Feb 2012
NCT04564612Completed59Est. Sep 2022
+14 more trials
Bristol Myers Squibb
17 programs
17
BMS-754807Phase 11 trial
BMS-986196Phase 11 trial
BMS-986278Phase 11 trial
BMS-986419Phase 14 trials
BMS-986435Phase 11 trial
+12 more programs
Active Trials
NCT01525823Completed26Est. Apr 2012
NCT05852769Completed18Est. Aug 2023
NCT07422298Not Yet Recruiting32Est. Jun 2026
+32 more trials
Regeneron
17 programs
17
DupilumabPhase 1Monoclonal Antibody
DupilumabPhase 1Monoclonal Antibody
EvinacumabPhase 1Monoclonal Antibody1 trial
FasinumabPhase 1Monoclonal Antibody1 trial
REGN1033Phase 11 trial
+12 more programs
Active Trials
NCT03146416Completed96Est. Jun 2018
NCT02516618Completed72Est. Feb 2016
NCT02943239Completed82Est. Apr 2019
+12 more trials
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
14 programs
14
AtorvastatinPhase 1Small Molecule5 trials
BaricitinibPhase 1Small Molecule1 trial
BaricitinibPhase 1Small Molecule1 trial
EvacetrapibPhase 11 trial
EvacetrapibPhase 15 trials
+9 more programs
Active Trials
NCT05327595Completed80Est. Apr 2024
NCT04270370Completed72Est. Jun 2021
NCT04047940Completed32Est. Feb 2020
+18 more trials
Insmed
InsmedBRIDGEWATER, NJ
9 programs
9
BrensocatibPhase 11 trial
BrensocatibPhase 11 trial
BrensocatibPhase 11 trial
C16TRPhase 11 trial
INS1007Phase 11 trial
+4 more programs
Active Trials
NCT06178783Completed20Est. Jan 2024
NCT05826574Completed32Est. Jul 2023
NCT05965570Completed22Est. Sep 2023
+6 more trials
AbbVie
8 programs
7
ABBV-552Phase 13 trials
DSM265 50% SDD granulesPhase 11 trial
DSM265-TPGS 34% SDD, 400 mg fastedPhase 11 trial
GalicaftorPhase 13 trials
RavagalimabPhase 1Monoclonal Antibody1 trial
+3 more programs
Active Trials
NCT00114114Completed177Est. Nov 2017
NCT06278766Completed8Est. Apr 2024
NCT05771428Completed263Est. Sep 2024
+9 more trials
Astellas
AstellasChina - Shenyang
8 programs
8
14C-labeled ASP0367Phase 11 trial
ASP1128Phase 11 trial
ASP6858Phase 11 trial
ASP8062Phase 11 trial
MA-0211Phase 11 trial
+3 more programs
Active Trials
NCT05217901Completed9Est. May 2022
NCT04742517Completed102Est. Sep 2018
NCT02359032Completed88Est. Jan 2016
+5 more trials
argenx
8 programs
8
ARGX-113Phase 11 trial
ARGX-113 with rHuPH20Phase 11 trial
ARGX-117Phase 11 trial
ARGX-119Phase 11 trial
ARGX-124Phase 11 trial
+3 more programs
Active Trials
NCT03457649Completed62Est. Feb 2017
NCT04073589Completed33Est. Sep 2019
NCT04532125Completed110Est. Aug 2022
+5 more trials
Denali Therapeutics
7
BIIB122Phase 1
DNL151Phase 11 trial
DNL201Phase 11 trial
DNL343Phase 11 trial
DNL343Phase 11 trial
+2 more programs
Active Trials
NCT04557800CompletedEst. Feb 2021
NCT04551534CompletedEst. Aug 2018
NCT04268784CompletedEst. Aug 2021
+2 more trials
Sanofi
7 programs
7
CaplacizumabPhase 1Monoclonal Antibody1 trial
MAGNE-B6 Oral SolutionPhase 11 trial
MidazolamPhase 11 trial
VenglustatPhase 1Small Molecule1 trial
VenglustatPhase 1Small Molecule1 trial
+2 more programs
Active Trials
NCT02189733Completed24
NCT06386211Completed24Est. Aug 2024
NCT01544140Completed16Est. Jul 2012
+4 more trials
mAbxience
7 programs
7
MB02Phase 11 trial
MB02Phase 11 trial
MB02Phase 11 trial
MB02-SPPhase 11 trial
MB04Phase 11 trial
+2 more programs
Active Trials
NCT04238650Completed49Est. Dec 2019
NCT03293654Completed114Est. May 2019
NCT04238663Completed115Est. Mar 2020
+4 more trials
Akebia Therapeutics
5
AKB-6548Phase 11 trial
AKB-6548Phase 11 trial
AKB-9090Phase 11 trial
CelecoxibPhase 1Small Molecule1 trial
VadadustatPhase 1Small Molecule1 trial
Active Trials
NCT02062203CompletedEst. Apr 2014
NCT02327546CompletedEst. Feb 2015
NCT07429006Not Yet RecruitingEst. Dec 2026
+2 more trials
Amgen
5 programs
5
AMG 510Phase 11 trial
AMG 853Phase 11 trial
Apremilast Immediate ReleasePhase 11 trial
AvacopanPhase 11 trial
CC-11050Phase 11 trial
Active Trials
NCT05550129Completed13Est. Nov 2019
NCT01124279Completed43Est. Oct 2010
NCT02236988Completed80Est. Sep 2014
+2 more trials
Crinetics Pharmaceuticals
5
AtumelnantPhase 11 trial
CRN00808Phase 11 trial
CRN01941 Oral SolutionPhase 11 trial
CRN04894 Oral SolutionPhase 11 trial
[14C]-CRN00808Phase 11 trial
Active Trials
NCT07221084Completed21Est. Feb 2026
NCT03276858Completed99Est. Apr 2018
NCT03936166Completed57Est. Dec 2019
+2 more trials
VP
5
TasimelteonPhase 11 trial
TasimelteonPhase 11 trial
TasimelteonPhase 11 trial
TasimelteonPhase 11 trial
tradipitantPhase 11 trial
Active Trials
NCT01540500Completed24Est. Mar 2012
NCT01477619Completed60Est. Jan 2012
NCT01402076Completed24Est. Aug 2011
+2 more trials
M&
Merck & Co.RAHWAY, NJ
4 programs
3
GLA-AFPhase 11 trial
Klaribact 500 mg Clarithromycin TabletPhase 11 trial
MK-6183Phase 11 trial
NeurogabinN/A1 trial
Active Trials
NCT05436886CompletedEst. Sep 2013
NCT01397604CompletedEst. Mar 2013
NCT05436769CompletedEst. Dec 2012
+1 more trials
GH Research
4 programs
4
5 Methoxy N,N DimethyltryptaminePhase 11 trial
5 Methoxy N,N DimethyltryptaminePhase 11 trial
5 Methoxy N,N DimethyltryptaminePhase 11 trial
5 Methoxy N,N DimethyltryptaminePhase 11 trial
Active Trials
NCT04640831CompletedEst. Oct 2019
NCT05753956CompletedEst. Nov 2023
NCT06511947RecruitingEst. Feb 2025
+1 more trials

+100 more companies

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
ModernamRNA-1273.712
Novo NordiskSemaglutide
Gilead SciencesGenvoya Oral dose
Pfizerartesunate sachets
PfizerNelfinavir
PfizerNelfinavir
PfizerNelfinavir
TakedaTAK-881
TakedaSoticlestat
TakedaSHP643
TakedaSHP643
NovartisTreatment A
Eli Lilly and CompanyAtorvastatin
NovartisTreatment A
Eli Lilly and CompanyEvacetrapib

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 18,113 patients across 50 trials

NCT06634797ModernamRNA-1273.712

A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age

Start: Oct 2024Est. completion: Jan 20251,000 patients
Phase 4Completed

Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc

Start: Dec 2019Est. completion: Feb 2020104 patients
Phase 4Completed

Analysis of Crushed and Whole Tablet Genvoya

Start: Apr 2019Est. completion: Nov 202112 patients
Phase 4Completed
NCT00875030Pfizerartesunate sachets

A Study Comparing Blood Levels After Single-Dose Administration Of Artesunate Sachets (Pfizer) Versus Single-Dose Administration Of Arsuamoon® Tablets (Guilin-China) In Healthy Subjects

Start: Jun 2009Est. completion: Jun 200940 patients
Phase 4Completed

Safety Of VIRACEPT® 625mg Administered To HIV-Infected Women During Pregnancy

Start: Mar 2006Est. completion: Nov 200716 patients
Phase 4Completed

Thorough QT Study of Nelfinavir

Start: Mar 2006Est. completion: Jun 200668 patients
Phase 4Completed

A Study To Estimate The Effect Of Omeprazole On The Pharmacokinetics Of Nelfinavir In Healthy Subjects

Start: Nov 2005Est. completion: Jan 200620 patients
Phase 4Completed

A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases

Start: Nov 2024Est. completion: Jan 202939 patients
Phase 3Recruiting

A Study Evaluating Soticlestat in Participants With Dravet Syndrome or Lennox-Gastaut Syndrome Who Have Been Exposed to Fenfluramine

Start: Apr 2024Est. completion: Aug 20241 patients
Phase 3Terminated

A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)

Start: Jun 2022Est. completion: Nov 202320 patients
Phase 3Completed

Efficacy and Safety of Lanadelumab (SHP643) in Japanese Participants With Hereditary Angioedema (HAE)

Start: Dec 2019Est. completion: Aug 202112 patients
Phase 3Completed

A Randomized Study to Evaluate the Effect of Reminder Notifications and Motivational/Adaptive Messaging on Treatment Adherence

Start: Jul 2018Est. completion: Jan 20197 patients
Phase 3Terminated

A Study of Evacetrapib (LY2484595) in Combination With Atorvastatin in Japanese Participants With Primary Hypercholesterolemia

Start: Jan 2015Est. completion: Nov 2015149 patients
Phase 3Terminated

Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.

Start: Nov 2014Est. completion: Dec 2017161 patients
Phase 3Completed

A Study of Evacetrapib (LY2484595) in Japanese Participants With Primary Hypercholesterolemia

Start: Nov 2014Est. completion: Dec 201554 patients
Phase 3Terminated

A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol

Start: Oct 2014Est. completion: Dec 2015366 patients
Phase 3Terminated

Phase III Study of Intramuscular TAK-816 in Healthy Infants

Start: Mar 2014Est. completion: Mar 201531 patients
Phase 3Completed

A Study of Evacetrapib in High-Risk Vascular Disease

Start: Oct 2012Est. completion: Jul 201612,092 patients
Phase 3Terminated

DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.

Start: Feb 2026Est. completion: Oct 202930 patients
Phase 2/3Not Yet Recruiting

DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations

Start: Nov 2024Est. completion: Oct 202930 patients
Phase 2/3Recruiting

Efficacy, Safety and Tolerability Study of Chloroprocaine 3% Gel Eye Drops in Healthy Volunteers

Start: Jun 2020Est. completion: Dec 202096 patients
Phase 2/3Completed

A Study of REGN7544 for the Treatment in Adult Patients With Sepsis-Induced Hypotension

Start: May 2025Est. completion: Apr 202676 patients
Phase 2Active Not Recruiting

Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma

Start: Feb 2024Est. completion: Mar 203130 patients
Phase 2Recruiting

Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease

Start: Jun 2023Est. completion: Sep 2024263 patients
Phase 2Completed

A Study to Evaluate the Efficacy, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Start: Jan 2023Est. completion: Feb 202518 patients
Phase 2Terminated

Ritlecitinib for Cicatricial Alopecia

Start: Dec 2022Est. completion: Mar 202550 patients
Phase 2Completed

Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma

Start: Nov 2021Est. completion: Sep 202968 patients
Phase 2Recruiting

Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis

Start: Sep 2021Est. completion: Jun 202348 patients
Phase 2Terminated
NCT04750759BayerNiclosamide

Safety and Preliminary Efficacy of the Combination of Niclosamide and Camostat

Start: Feb 2021Est. completion: Oct 20214 patients
Phase 2Terminated

Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other Causalities

Start: Aug 2020Est. completion: Feb 202441 patients
Phase 2Terminated

A Research Study Investigating Mim8 in People With Haemophilia A

Start: Jan 2020Est. completion: Oct 2023275 patients
Phase 2Completed

Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis

Start: Feb 2019Est. completion: Nov 20200
Phase 2Withdrawn

A Multicenter, Open-label, Pilot Study of Soticlestat (TAK-935/OV935) in Participants With 15Q Duplication Syndrome (Dup 15q) or Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder (ARCADE STUDY)

Start: Sep 2018Est. completion: Jul 202020 patients
Phase 2Completed

A Study of Soticlestat in Adults and Children With Rare Epilepsies

Start: Jul 2018Est. completion: Jul 2025156 patients
Phase 2Terminated

Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

Start: Aug 2017Est. completion: Jul 202729 patients
Phase 2Active Not Recruiting

Assess Bronchodilator Effect QVM149 Dosed Either in the Morning or Evening Compared to Placebo in Patients With Asthma

Start: Jun 2017Est. completion: Feb 201838 patients
Phase 2Completed

Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children

Start: Apr 2017Est. completion: Dec 2020200 patients
Phase 2Completed

Long-Term Immunogenicity of the Norovirus GI.1/GII.4 Bivalent Virus-like Particle (VLP) Vaccine (NoV Vaccine) in Adults

Start: Feb 2017Est. completion: Jul 2021528 patients
Phase 2Completed
NCT02038907TakedaHepatitis A Vaccine

Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent VLP Vaccine

Start: Mar 2014Est. completion: Jun 2015420 patients
Phase 2Completed

A Study of LY2484595 in Japanese Subjects

Start: Jun 2011Est. completion: Mar 2012165 patients
Phase 2Completed

A Long Term Safety Study Of Lersivirine For The Treatment Of HIV-1 Infection In Subjects Who Have Completed Treatment With Lersivirine In Studies A5271015 And A5271022

Start: Feb 2011Est. completion: Apr 2013108 patients
Phase 2Terminated

A Study of LY2484595 in Patients With High LDL-C or Low HDL-C

Start: Apr 2010Est. completion: Jun 2011398 patients
Phase 2Completed

A Study in People With High Cholesterol

Start: Jul 2005Est. completion: Sep 2006300 patients
Phase 2Completed
NCT01367587Bausch HealthIV Methylnaltrexone

Safety and Gastrointestinal Effects of Intravenous Methylnaltrexone

Start: Apr 2002Est. completion: Jul 2002
Phase 2Completed

Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

Start: Nov 2024Est. completion: Dec 203449 patients
Phase 1/2Recruiting

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

Start: Oct 2022Est. completion: Oct 2026260 patients
Phase 1/2Recruiting

Evaluate the Safety and Tolerability, as Well as the Pharmacokinetic and Pharmacodynamic Profiles of Single and Multiple Doses of Eplontersen Administered Subcutaneously to Healthy Volunteers and Patients With Hereditary Transthyretin-Mediated Amyloidosis (hATTR ).

Start: Dec 2018Est. completion: Feb 202047 patients
Phase 1/2Completed

Pharmacokinetics, Pharmacodynamics Profile and Tolerance of P03277 in Healthy Subjects and Patients With Brain Lesions

Start: Nov 2013Est. completion: Apr 2015142 patients
Phase 1/2Completed

SAD and MAD Study of AKB-9090 in Healthy Adult Participants

Start: Mar 2026Est. completion: Dec 2026
Phase 1Not Yet Recruiting

A Study to Evaluate the Effect of BMS-986278 on Cardiac Repolarization in Healthy Participants

Start: Feb 2026Est. completion: Jun 202632 patients
Phase 1Not Yet Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
6 actively recruiting trials targeting 18,113 patients
30 companies competing in this space